Armistice Capital, LLC Reports New 9.99% Stake in Estrella Immunopharma, Inc. (ESLA)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G regarding their holdings in Estrella Immunopharma, Inc. (ESLA). The filing discloses that the reporting persons have acquired a significant stake in the company, reporting beneficial ownership of 4,280,375 shares of common stock. This position represents approximately 9.99% of the issuer's outstanding shares. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Consequently, Armistice Capital and Steven Boyd share voting and dispositive power over these securities. The filing indicates that the acquisition was made in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing establishes a new substantial position for the reporting persons as of the event date of March 31, 2026, moving from a previously reported 0% ownership interest to nearly 10%.